PYC Therapeutics (ASX:PYC) said the US Food and Drug Administration has granted Rare Pediatric Disease (RPD) designation to its drug candidate VP-001 for treating retinitis pigmentosa type 11, a blinding childhood eye disease, according to a Monday filing with the Australian bourse.
Currently in phase 1/2 studies, VP-001 is set to enter a potentially registrational trial in 2025, the filing said.
The RPD designation supports the development of therapies for serious, rare pediatric conditions, the filing added.
Shares of the company fell almost 4% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.